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Abstract
Background: The discovery of small non-coding RNAs and the subsequent analysis of microRNA expression
patterns in human cancer specimens have provided completely new insights into cancer biology. Genetic and
epigenetic data indicate oncogenic or tumor suppressor function of these pleiotropic regulators. Therefore, many
studies analyzed the expression and function of microRNA in human breast cancer, the most frequent malignancy
in females. However, nothing is known so far about microRNA expression in male breast cancer, accounting for
approximately 1% of all breast cancer cases.
Methods: The expression of 319 microRNAs was analyzed in 9 primary human male breast tumors and in epithelial
cells from 15 male gynecomastia specimens using fluorescence-labeled bead technology. For identification of
differentially expressed microRNAs data were analyzed by cluster analysis and selected statistical methods.
Expression levels were validated for the most up- or down-regulated microRNAs in this training cohort using real-
time PCR methodology as well as in an independent test cohort comprising 12 cases of human male breast
cancer.
Results: Unsupervised cluster analysis separated very well male breast cancer samples and control specimens
according to their microRNA expression pattern indicating cancer-specific alterations of microRNA expression in
human male breast cancer. miR-21, miR519d, miR-183, miR-197, and miR-493-5p were identified as most
prominently up-regulated, miR-145 and miR-497 as most prominently down-regulated in male breast cancer.
Conclusions: Male breast cancer displays several differentially expressed microRNAs. Not all of them are shared
with breast cancer biopsies from female patients indicating male breast cancer specific alterations of microRNA
expression.
Background
Breast cancer in men accounts for approx. 1% of all
breast cancers [1]. Despite a statistically significant raise
in the incidence of male breast cancer over the last
25 years it is still a quite rare disease. Therefore, therapy
is mainly based on what is known from female breast
cancer. Despite the fact that randomized controlled pro-
spective trials are not possible due to the low incidence,
it is clear from retrospective analyses that male breast
cancer is not exactly the same entity as female breast
cancer [2].
The discovery of a new class of small non-protein-
coding RNAs with pleiotrop i cr e g u l a t o r yf u n c t i o n s
("microRNAs”) has substantially changed our under-
standing of tumor development and progression [3].
New molecular mechanisms, new diagnostic markers
and new potential therapeutic targets have been discov-
ered during the last years in the field of microRNA
research. Consequentially, several studies revealed speci-
fic changes in microRNA expression in female breast
cancer, the most frequent malignancy in females (see [4]
and references therein). But so far only a single study,
conducted nearly in parallel to the work described
inhere, analyzed the expression of microRNA genes in
human male breast cancer [5].
Therefore, we analyzed the expression pattern of
319 microRNAs in 9 male breast cancer specimens as
* Correspondence: Lehmann.Ulrich@MH-Hannover.de
1Institute of Pathology, Medizinische Hochschule Hannover, D-30625
Hannover, Germany
Lehmann et al. BMC Cancer 2010, 10:109
http://www.biomedcentral.com/1471-2407/10/109
© 2010 Lehmann et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.wells as in 15 epithelium fractions from male gyneco-
mastia specimens using fluorescence-labeled bead tech-
nology from Luminex™. Results were validated for the
most differentially regulated microRNAs in these
9 tumors, the control samples and an independent test
series of 12 male breast cancer specimens using stem-
loop primer based real-time PCR methodology (Taq-
Man™ assays from Applied Biosystems).
Only formalin-fixed paraffin-embedded (FFPE) speci-
mens were available for this study. However, in a pre-
vious study we could demonstrate that RNA extracted
from FFPE specimens is a suitable substrate for micro-
RNA profiling using fluorescence-labeled bead technol-
ogy from Luminex™ [6].
Results
Characterization of the study cohort
For the comprehensive determination of the microRNA
expression profile of human male breast cancer 9 speci-
mens were retrieved from the archives. The primary
selection criteria were tumor size and tumor cell content,
because several microgram of total RNA are required for
the full profiling with five different bead pools (see Mate-
rials and Methods). All tumors were grade 2 or 3, with a
mean proliferation rate of 20% (as determined by MIB1
l a b e l i n g ,m e d i a n :2 0 % ,r a n g e :1 0-4 0 % ) .T h e yw e r ea l l
estrogen and androgen receptor positive, all but one were
also progesterone receptor positive, but negative for Her2
overexpression, p63 expression and expression of basal
cytokeratines 5 and 14, thus representing typical male
breast cancer cases [1].
The 12 additional cases for independent validation
were comprised by 6 primary invasive carcinomas, 3
local recurrences, and 3 metastases. The distribution of
tumor grade, proliferation rate and the immunohisto-
chemically determined tum o rm a r k e rp r o f i l e sw e r e
very similar to the first nine cases under study. A
detailed description of all 21 specimens is provided in
Table 1.
For comparison a series with 15 male gynecomastia
specimens was analyzed representing a benign prolifera-
tive condition of the ductal epithelium.
microRNA profiling of human male breast cancer
The expression of 319 microRNAs was analyzed in 9 pri-
mary human male breast cancer specimens using fluores-
cence-labeled bead technology. As a control the expression
of these 319 microRNAs was measured in 15 epithelial cell
fractions from male gynecomastia specimens, which were
pooled in 4 mixes due to low RNA yield.
Unsupervised clustering of all microRNA expression
data separated very well the carcinoma specimens from
the pools of control samples, clearly indicating cancer-
specific alterations of microRNA expression in male
breast cancer (Figure 1).
T-test based analysis for comparison of carcinoma and
normal samples identified several differentially expressed
microRNAs (Figure 2), among them miR-21 reported to
be overexpressed in female breast cancer and miR-145
reported to be down-regulated in female breast cancer
[7,8]. Up-regulation of miR-519d, miR-183, miR197, and
miR-493-5p (more than twofold in comparison to gyne-
comastia, see Table 2) has not been reported so far in
female breast cancer.
A detailed analysis revealed 33 statistically signifi-
cantly up-regulated and 21 statistically significantly
down-regulated microRNAs in human male breast can-
cer in comparison to male gynecomastia specimens
(Table 2). Strongest up-regulation was found for miR-
21, already described to be significantly up-regulated in
female breast cancer ([4] and references therein) and
other solid tumors. ([3] and references therein)
Table 1 Overview of all cases analysed in this study
age grade ER PR AR MIB Her2 p63 CK5/
14
MBC1 61 DIC 2 8 3 7 30 1 - -
MBC3 63 DIC 3 6 6 5 25 0 - -
MBC6 64 DIC,
rec
2 5 0 7 40 2 - -
MBC8 62 DIC 2 6 8 5 10 1 - -
MBC9 53 DIC 3 7 8 8 25 1 - -
MBC10 47 DIC 2 8 5 7 20 1 - -
MBC11 51 DIC 2 5 5 5 15 0 - -
MBC12 74 DIC 2 7 8 6 10 0 - -
MBC13 71 DIC 2 0
MBC2 62 Met 8 6 6 10 0 - -
MBC4 69 Met 4 6 5 30 1 - -
MBC5 66 DIC,
rec
2 6 0 4 20 0 - -
MBC7 53 Met 8 7 7 15 0 - -
MBC15 68 DIC,
rec
2 8 8 6 15 0 - -
MBC16 63 DIC 3 8 7 6 20 2 - -
MBC20 70 DIC 2 6 4 6 10 2 - -
MBC22 41 DIC 3 7 7 6 15 0 - -
MBC23 69 DIC 3 6 4 4 20 1 - -
MBC24 67 DIC 3 5 7 5 35 0 - -
MBC26 55 DIC 3 7 8 6 10 0 - -
MBC27 83 inv.pap. 2 7 4 7 40 3 - -
bold: used for the comprehensive profiling
ER, PR, and AR staining was scored according to the Allred score
MBC5 is a local recurrence of the primary carcinoma MBC3
MBC13: specimen was no longer available for further characterization,
therefore incomplete marker profile
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real-time PCR
In order to validate the results of the profiling experi-
ments, the expression level of the two most up-regulated
(miR-21, miR-519d) and the two most down-regulated
(miR-497, miR-145) microRNAs were validated in the
carcinoma training cohort (n = 9), an independent carci-
noma test cohort (n = 12) and the four control samples
using real-time PCR methodology (stem-loop primer-
based kits from Applied Biosystem). Correlation analysis
revealed a good correlation between the real-time PCR
data (stem loop primer PCR) and the Luminex™ data
(fluorescence labeled beads) for miR-21 (r = 0.93),
miR-145 (r = 0.513), and miR-497 (0.71).
Welch-based t-test demonstrates a statistically signifi-
cant difference between carcinoma samples and the con-
trols for miR-21, miR-145, and miR-497, but only a
trend for miR-519d (Figure 3).
Figure 1 Unsupervised cluster analysis of the expression level of 319 microRNAs in 9 male breast cancer and 4 pools of gynecomastia
specimens (pools of 3 or 4 individual samples each). For this analysis the normalization was performed as described by Blenkiron et al. [26]
with inter-pool normalization.
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cancer
To further explore our findings, we analyzed the expres-
sion of several target genes of miR-21. We concentrated
on miR-21, because it is the most significantly up-regu-
lated miR-21 in our study and several validated target
genes are described in the literature (see [9] and references
therein, see also the new database miRecords [10]). Quan-
titative real-time RT-PCR was employed to measure
mRNA levels of target genes, because quantification of
protein expression levels in archival clinical specimens is
difficult and depends on the availability of suitable antibo-
dies. Mean expression in carcinoma specimens compared
to the control group was measured for MASPIN, PDCD4,
GLCCl1, BMPR-II, and APAF-1. Whereas no clear differ-
ences were discernible for BMPR-II and APAF-1, respec-
tively (data not shown), differential expression, albeit to a
different extent, was found for MASPIN, PDCD4 and
GLCCl1 (Figure 4). GLCCl1 showed a highly significant
reduction in the tumor specimens in comparison to the
control group. MASPIN showed only a weak reduction
whereas PDCD4 didn’t show any difference in this presen-
tation of the data (Figure 4A). However, if the mRNA
expression level is correlated to the miR-21 expression
level case-by case, a clear inverse correlation is discernible
for MASPIN (Figure 4B), and much more pronounced for
PDCD4 (Figure 4C), one of the best studied target genes
of miR-21 [9,11]. Nearly all measurements for PDCD4 are
within the 95% confidence interval (data not shown).
Discussion
Cluster analysis of microRNA expression profiles
revealed cancer-specific alterations of microRNA expres-
sion in human male breast cancer. Many, but not all of
these alterations are shared with female breast cancer of
the ductal invasive type. From the 20 most differentially
regulated microRNAs (10 most up-regulated and
10 most down-regulated, see Table 2) 7 are shared with
female breast cancer (miR-21, miR-127, miR-122a, miR-
135b, miR-140, miR-497, miR-145). All 10 most up-
regulated microRNAs are already reported to be
expressed at an elevated level in human malignancies
[7,12-17]. The most strongly up-regulated microRNA
miR-21 is described by several studies to be markedly
up-regulated in various epithelial malignancies, among
them female breast cancer [18]. The most prominently
down-regulated microRNAs miR-145 and miR-497 are
already identified as down-regulated in female breast
cancer [7,8]. Further studies attribute already quite well
characterized tumor-suppressor function to miR-145
and miR-497 in other malignancies as well [16,19,20].
miR-145, whose most prominent validated target gene is
c-myc [21], was already found to be down-regulated in
male breast cancer by Fassan et al. [5].
Figure 2 t-test (p = 0.01) for the identification of differentially expressed microRNAs in human male breast cancer.
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discernible negative correlation between miR-21 and
miR-21 target gene expression could be demonstrated
(Figure 4). However, not all reported miR-21 target
genes tested in this study showed reduced mRNA
expression in male breast cancer specimens indicating
Table 2 List of microRNAs differentially expressed in
human male breast cancer
UID Mean MBC
(log2)
Mean Mix
(log2)
FoldChange p-value
hsa-miR-21 -0,03 -2,38 5,11 0,004029143
hsa-miR-
519d
0,05 -1,46 2,85 0,004768175
hsa-miR-
183
0,23 -1,26 2,82 0,003398121
hsa-miR-
197
0,01 -1,03 2,05 0,002805108
hsa-miR-
493-5p
-0,07 -1,08 2,02 0,003438789
hsa-miR-
142-3p
0,00 -0,98 1,98 0,00169614
hsa-miR-
138
0,33 -0,62 1,93 0,00024239
hsa-miR-
127
0,12 -0,78 1,87 0,00040025
hsa-miR-
370
0,28 -0,60 1,84 0,005644958
hsa-miR-
122a
0,19 -0,66 1,81 0,00143915
hsa-miR-
514
0,36 -0,49 1,80 0,000596294
hsa-miR-
302c*
0,48 -0,34 1,76 0,001330654
hsa-miR-
502
0,35 -0,45 1,74 0,000582627
hsa-miR-
107
-0,01 -0,77 1,69 0,000812296
hsa-miR-
485-5p
0,48 -0,25 1,66 0,001501971
hsa-miR-
500
0,22 -0,50 1,64 0,00600779
hsa-miR-
433
0,32 -0,36 1,60 0,000983356
hsa-miR-
148a
0,05 -0,62 1,59 0,000878915
hsa-miR-
509
0,37 -0,24 1,53 0,000637106
hsa-miR-
409-5p
0,19 -0,38 1,48 0,000646352
hsa-miR-
512-5p
0,33 -0,22 1,46 0,002213783
hsa-miR-
453
0,28 -0,26 1,45 0,000888411
hsa-miR-
200a
0,05 -0,48 1,44 0,000906633
hsa-miR-
328
0,13 -0,38 1,42 0,003384969
hsa-miR-
103
-0,08 -0,60 1,42 0,000858599
hsa-miR-
375
0,06 -0,44 1,41 0,002278685
hsa-miR-
154*
0,14 -0,35 1,40 0,002861893
hsa-miR-
182
0,24 -0,23 1,38 0,004889343
hsa-miR-
515-3p
0,16 -0,30 1,38 0,00254786
Table 2: List of microRNAs differentially expressed in
human male breast cancer (Continued)
hsa-miR-
148b
0,27 -0,19 1,37 0,000346533
hsa-miR-
365
0,00 -0,31 1,23 0,003164365
hsa-miR-
181a
0,05 -0,21 1,20 0,006523063
hsa-miR-
510
0,21 -0,04 1,19 0,005192826
hsa-miR-
518f*
-0,03 0,20 -1,17 0,001226005
hsa-miR-
20b
-0,12 0,13 -1,19 0,004383712
hsa-miR-
520h
-0,15 0,13 -1,22 0,009803676
hsa-miR-
412
-0,18 0,14 -1,24 0,005788243
hsa-miR-
34a
-0,21 0,14 -1,27 0,005886412
hsa-miR-
520c
-0,14 0,22 -1,28 0,004330261
hsa-miR-
507
-0,12 0,27 -1,31 0,00018419
hsa-miR-
518d
-0,22 0,20 -1,34 0,004924138
hsa-miR-95 -0,16 0,27 -1,35 0,000709481
hsa-miR-
146a
-0,19 0,25 -1,35 0,004129367
hsa-miR-
516-3p
-0,23 0,23 -1,38 0,000300035
hsa-miR-
216
-0,14 0,32 -1,38 0,000500204
hsa-miR-
544
-0,23 0,24 -1,38 0,009547717
hsa-miR-
511
-0,13 0,34 -1,39 0,003257481
hsa-miR-
542-5p
-0,25 0,24 -1,40 0,001777145
hsa-miR-
144
-0,16 0,33 -1,41 0,004720278
hsa-miR-
520e
-0,25 0,25 -1,41 0,000266494
hsa-miR-
140
-0,28 0,28 -1,47 0,00867657
hsa-miR-
135b
-0,25 0,40 -1,57 0,000641931
hsa-miR-
497
-0,29 0,36 -1,57 0,001634003
hsa-miR-
145
-0,37 0,44 -1,75 0,007261167
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ulation under many circumstances.
A recent publication describes the kallikrein family
of serine proteases as potential targets of miR-519d,
the second most prominently up-regulated microRNA
in male breast cancer [22]. However, the identification
of target genes specific for miR-519d is especially chal-
lenging because it shares target sequence specificity
with miR-17-5p, miR-20 A and B, as well as miR-106
A and B. Other microRNAs overexpressed more than
twofold in human male breast cancer, but not yet
described in female breast cancer are miR-183, miR-
197, miR-493-5p, and 519d. However, these micro-
RNAs are described as up-regulated in other human
malignancies [12,14-16]. miR-183 is destabilizing a ubi-
quitine-ligase (bTrCP1, ref. [23]), miR-197 targets the
tumor-suppressor FUS1 [15], whereas for miR-493-5p
convincing experimental data for a validated target
gene are still missing. The most prominent target gene
with a high score predicted by TargetScanHuman
(release 5.1, http://www.targetscan.org) is FOXP2
which plays an important role in neural mechanism
involved in language development [24].
A limitation of this study might be that completely
normal male breast epithelium from healthy individuals
is principally not available in sufficient amounts for
molecular studies. Therefore, we chose male gyneco-
mastia specimens for comparison which represent a
condition of increased but benign ductal epithelial
proliferation [25]. This serves as a suitable reference
for the identification of alterations in microRNA
expression due to malignant hyperproliferation, which
takes place in male breast cancer. This approach has
the advantage that it filters out all simply proliferation
associated changes in microRNA expression.
A conceptual advantage of the Luminex™ approach is
the omission of any amplification step, which might
introduce a bias of unknown extent which is difficult to
control. The hybridization of probe and target sequence
in homogenous solution circumvents also all potential
artifacts due to the inhomogeneous reaction conditions
at the boundary surface of a microarray. A potential dis-
advantage is the fact that the hybridization takes place
in five separate tubes. This requires inter-pool normali-
zation which might introduce a bias as well (see below).
Figure 3 Expression of the two most strongly up-regulated
and the two most strongly down-regulated microRNAs in male
breast cancer and control samples as determined by real-time
PCR. Relative expression levels for every sample were calculated by
normalizing to the mean expression level of the three small RNA
species RNU24, U54, and Z-30. All measurements were performed
independently two times. Statistical significance of differences
between cancer (MBC) and control samples (C) were calculated
using Mann-Whitney-U-test.
Figure 4 Expression of miR-21- target genes in male breast
cancer in comparison to the control samples (A), correlation of
miR-21 expression with the mRNA level of MASPIN (B) and
PDCD4 (C) in male breast cancer specimens. Relative expression
levels for every sample were calculated by normalizing to the mean
expression level of two reference genes (bGUS and TBP). For every
target gene the mean of the expression level in the control group
was set equal to 1. Every individual measurement in the tumor
samples was then normalized to this expression level. All
measurements were performed independently two times. Error bars
indicate standard deviation of the mean.
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based approaches quite a lot of total RNA is required.
It was decided to perform inter-pool normalization as
described by Blenkiron et al. [26], because the spike-in
controls provided by Luminex™ and contained within
every pool showed some variation between the five
pools. A detailed analysis for selected targets comparing
this normalization strategy with the one recommended
by Luminex™ (based on the spike-in controls) showed
that for individual microRNAs expression patterns
depend on the normalization strategy. But the expres-
sion patterns of the most differentially regulated genes
(validated independently by real-time PCR, see Figure 3)
were independent from the normalization strategy (data
not shown).
During the preparation of this manuscript Fassan et al.
published the microRNA expression profiling of 23 male
breast cancer specimens using a published microarray
platform [5]. Since the analytical platforms (microarray
versus fluorescence labeled beads with a different selec-
tion of represented microRNAs) and the study design
are different (all samples analyzed with the microarray
in Fassan etal. versus independent validation of results
obtained with the training set in a test set), the results
are not directly comparable. Therefore, these studies
lead to somewhat different results, though very similar
in scope and size.
The most prominently up-regulated microRNA in our
study is the well-known miR-21, described by several
studies to be up-regulated in female breast cancer as
well as in other solid tumors ([3] and references
therein). This finding serves as a very good internal con-
trol for our findings since the overexpression of this
microRNA in male breast cancer is an expected finding.
Interestingly, miR-21 was not found to be differentially
expressed in male breast cancer by Fassan et al.
A difference between the breast cancer series used by
Fassan et al., which is described in detail in a previous
publication [27], and the training and test cohort used
in this study is the prevalence of basal cytokeratine
(CK5/6 and CK14) expression. The total absence of
basal cytokeratines in our series is contrasted by nearly
20% of cases positive for basal cytokeratines in the series
used by Fassan etal. This might explain differences in
microRNA expression patterns. Therefore, in the future
a multi-institutional large-scale profiling approach
employing different methodologies for the analysis of
the very same set of samples is desirable.
Conclusion
In summary, we describe the identification of differen-
tially expressed microRNAs in human male breast can-
cer using fluorescence labeled bead methodology.
Several microRNAs are shared between female and male
breast cancer, but our data also suggest that clear differ-
ences exist between breast cancer arising in males and
females. Results were confirmed in the training set and
an independent test set using real-time PCR
methodology.
Methods
Patient Samples
21 specimens from 20 male patients with the clinically
and histopathologically confirmed diagnosis of breast
carcinoma in the period from 1995 to 2008 were
selected from the archive of the Institute of Pathology,
Medizinische Hochschule Hannover, Germany and ana-
lyzed anonymously following the guidelines of the local
Ethics committee ("Ethik-Kommission der Medizi-
nischen Hochschule Hannover”, head: Prof. Dr. Tröger).
For the comprehensive profiling of 319 microRNAs
(trainings set, n = 9) only tumors with a size greater
than 0.5 cm and a total RNA yield of at least 10 μg
were selected. If tumor cell content was below 75%,
tumor cells were manually microdissected from
unstained histological sections using an H&E stained
serial section as guidance. For a detailed description of
all carcinoma cases see Table 1.
As a reference for normal expression level the RNA
isolated from 15 male age-matched gynecomastia speci-
mens was pooled into four control samples ("mix 1 - 4”,
made up of three or four individual RNA preparations,
respectively) because the average RNA yield was quite
low due to the limited number of epithelial cells present.
Immunohistochemistry
Multi tissue arrays were constructed as described in
order to ensure homogenous staining quality for all spe-
cimens [28]. Two tissue cores per specimen were ana-
lyzed and scored in a blinded fashion. Mouse
monoclonal anti-ER (clone: 6F11), anti-PgR (clone: 16),
and anti-HER2 (clone: CB11) antibodies were purchased
from Ventana (Illkirch, France) and mouse monoclonal
anti-CK5/6 (clone: D5/16 B4), anti-p63 (clone: 4A4),
anti-MIB-1/Ki 67 (clone: MIB-1), and anti-androgen
receptor (anti-AR; clone: AR441) antibodies were pur-
chased from Dako (Glostrup, Denmark). The antibodies
used for immunohistochemistry formalin-fixed, paraffin-
embedded sections (3 μm) were deparaffinized in xylene
and dehydrated through graded alcohols. Slides were
rinsed thoroughly with Protein Blocking Agent (Ultra-
Tech HRP Streptavidin-Biotin Detection System, Beck-
m a nC o u l t e r ,F u l l e r t o n ,C A ,U S A ) .E n d o g e n o u s
peroxidase was blocked in 3% hydrogen peroxide
(H2O2) in methanol for 15 min. Antigen retrieval for
ER, PR, HER2, CK5/6, p63, MIB-1, and AR was done by
autoclaving at 121°C for 10 min in 0.1 mol/L citrate buf-
fer (pH 6). The sections were incubated with one of the
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body (predilution), anti-PgR antibody (predilution), anti-
HER2 antibody (predilution), anti-CK5/6 antibody
(1:100 dilution), anti-p63 antibody (1:50 dilution), anti-
MIB-1 antibody (1:50 dilution), and anti-AR antibody
(1:50 dilution) for 60 min at room temperature. Then,
the secondary biotinylated goat polyvalent antibody
(Beckman Coulter) was applied for 10 min at room tem-
perature. The sections were incubated with peroxidase-
conjugated streptavidin for 10 min and the reaction pro-
ducts were visualized using 3,3’-diaminobenzidine tetra-
hydrochloride (DAB) and H2O2. Counterstaining was
performed using hematoxylin. The slides were rinsed
with PBS after each stage of the procedure. As a nega-
tive control, all staining was also performed without the
first antibody. When >5% of the tumor cells were
stained with the antibody for p63 and CK 5/14, it was
categorized as positive for antigen expression. HER2
staining was scored following the HER2 testing guide-
lines for breast cancer. ER, PR and AR expression was
evaluated by the Allred score.
RNA isolation
Isolation of total RNA from FFPE specimens was per-
formed as described previously [29]. Following the
recommendations from Luminex Inc. no microRNA
enrichment was performed.
microRNA measurement using fluorescence labeled beads
Quantification of microRNAs hybridized to fluorescence
labeled beads was performed with a BioPlex 200™ from
Biorad (Bio-Rad Laboratories GmbH, München, Ger-
many) using the software Luminex IS™, version 2.3 from
Luminex (Austin, Texas, USA). All beads coated with
LNA probes complementary to mature microRNAs
were purchased from Luminex Inc. (Austin, Texas,
USA).
Prior to hybridization total RNA is labeled with biotin
which is later bound to a streptavidin-phycoerythrin
conjugate. For this purpose the FlexmiR™ MicroRNA
Labeling Kit from Luminex Inc. was used. For the com-
prehensive profiling of 319 microRNAs (FlexmiR™
human microRNA pool, version 8) 2.5 μgt o t a lR N A
were labeled following the protocol provided by the
manufacturer. The 319 different microRNA beads are
divided into 5 pools because there are not enough dif-
ferent fluorescence labels available to distinguish more
than 70 - 80 beads in a single tube. For every pool 0.5
μg of total RNA are required. Subsequent washing,
hybridization and analysis of samples were performed
exactly as described in the protocols provided by Lumi-
nex Inc.
The system was calibrated using the xMAP™ calibra-
tion control reagents from Luminex Inc. following the
recommendations of the manufacturer. Every run con-
tained a negative control for background subtraction
(water instead of RNA) and a positive control (total
human brain RNA from Ambion, provided by Luminex
Inc.).
microRNA measurement using real time-RT-PCR
technology
For the measurement of the expression levels of selected
microRNAs (mir-21, -145, -497, -519d) the real time-
RT-PCR-based detection methodology from ABI (Darm-
stadt, Germany) was used. Relative expression levels
were calculated using the constitutively expressed small
RNAs RNU24, U54, and Z-30 as endogenous controls.
All primers and probes were purchased from ABI.
cDNA synthesis and real-time PCR were performed fol-
lowing the protocols supplied by the manufacturer.
mRNA measurement using real time-RT-PCR technology
For the measurement of the expression level of selected
mir-21 target genes total RNA was transcribed to cDNA
as described in ref. [30]. For this purpose an aliquot
from the RNA preparation used for microRNA profiling
was used. Subsequent real-time RT-PCR using Sybr-
Green as detection reagent was performed as described
in ref. [31] with the same reference genes (bGUS and
TBP). The primer sequences for the miR-21 target
genes were taken from ref. [9].
Statistical analysis
The raw intensity values were processed according to
Blenkiron et al. [26]. Values smaller than 1 were equal-
ized to 1. All values were log transformed to a basis of
2. The background values derived from the negative
control were subtracted from all sample signals. A pool
to pool probe effect normalization was performed as
described by Blenkiron et al. [26]. Samples and miRNAs
were clustered unsupervised hierarchically with the
Eisen cluster software (EisenLab Cluster version 2.11)
using average linkage and uncentered correlation. Visua-
lization was performed with TreeView (version 1.60).
To compare the two groups (normal vs. carcinoma)
Welch based t-tests were carried out using R statistical
platform (version 2.80) and visualized using TIGR soft-
ware (MeV version 4.3, http://www.tm4.org).
The correlation between microRNA expression and
relative PCR CT-values was determined by Pearson pro-
duct moment correlation.
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